Adbiotech

ADBiotech is a biotech company built around an egg-yolk-derived immunoglobulin antibody (IgY) production platform, founded in 2000 and listed on KOSDAQ in 2022 via the technology special listing track.

Its core business is animal medicine and supplementary feed for disease prevention and treatment in livestock and aquaculture, positioned as an alternative to vaccines and antibiotics for cattle, swine, and poultry, alongside disinfectants for biosecurity.

More recently the company has supplied pet-healthcare products such as single-use artificial tears for companion animals domestically and has completed US FDA food facility registration to support overseas expansion.

On the human-use side, it has long supplied egg-yolk-protein ingredients that inhibit Helicobacter pylori and cholesterol absorption, and in 2021 it established a food/pharma business division that launched four health functional food products under the "Jayeonpore" brand, including menopause-support products for women and men and a probiotics line.

In June 2026 the company amended its articles of incorporation to add a broad set of new business purposes—medical and pharmaceutical R&D, bio reagents and medical devices, genetic engineering, protein/peptide drugs, drug delivery systems (DDS), nanotechnology-based diagnostics and therapeutics, and contract sales organization (CSO) services—signaling a shift toward a bio and digital healthcare-centered company.

That same month, Kim Do-hyung, a veterinarian and founder of CRO firm Notus (now HLB Biostep), was appointed sole CEO, and new board members with expertise in infectious disease, veterinary medicine, and pharmacology joined the company.

Competitors cited in the animal medicine and immune-antibody space include Woojin B&G, GC Veterinary Pharma, Biod, and Intron Biotechnology.

The company previously held an exclusive licensing agreement and received strategic investment from Kyoritsu Seiyaku, Japan's largest animal medicine company, and has also registered products and signed distribution agreements in China.

Annual revenue was KRW 10.63 billion in 2022, KRW 10.47 billion in 2023, KRW 11.14 billion in 2024, and KRW 12.90 billion in 2025—a slight dip in 2023 followed by two consecutive years of growth.

The operating loss, by contrast, narrowed for four straight years, from KRW -4.94 billion in 2022 to KRW -4.76 billion in 2023, KRW -4.12 billion in 2024, and KRW -3.50 billion in 2025, showing a gradual reduction in losses alongside top-line growth.

Net income attributable to owners, however, swung sharply—from a KRW +2.70 billion profit in 2022 to a KRW -2.86 billion loss in 2023, deteriorating further to KRW -7.95 billion in 2024 before narrowing to KRW -3.30 billion in 2025—reflecting substantial volatility from non-operating items.

On a quarterly basis, after posting revenue of KRW 3.63 billion, an operating loss of KRW -1.76 billion, and a net loss of KRW -4.80 billion in Q3 2025, the company recorded a rare operating profit of KRW +0.35 billion on revenue of KRW 2.97 billion in Q4 2025, with net income surging to KRW +6.95 billion—a figure far exceeding the operating profit that points to a large one-off non-operating item.

In Q1 2026 the operating loss widened again to KRW -1.06 billion and the net loss returned to KRW -5.39 billion, while in Q2 2026 the operating loss widened further to KRW -1.94 billion even as the net loss narrowed sharply to KRW -0.28 billion, again showing a gap between operating and net results.

On the balance sheet, the debt ratio spiked from 91.6% in 2022 to 675.6% in 2024 before easing to 257.5% in 2025, reflecting equity erosion from the 2024 loss followed by capital reinforcement through the 2025-2026 equity placement and CB issuances.

Operating cash flow was positive only in 2023 at KRW +0.31 billion, with outflows in the other years of KRW -8.59 billion (2022), KRW -4.09 billion (2024), and KRW -1.32 billion (2025).

Korea's animal medicine market is sensitive to seasonally recurring livestock disease outbreaks such as highly pathogenic avian influenza, creating parallel demand for stronger biosecurity and for technologies that can substitute for vaccines and antibiotics.

ADBiotech targets this substitution demand through its IgY immune-antibody technology but competes with domestic animal medicine and bio companies including Woojin B&G, GC Veterinary Pharma, Biod, and Intron Biotechnology.

The domestic pet healthcare market is a fast-growing segment, and the company is attempting to broaden its lineup beyond small items such as artificial tears into oral, skin, and nutrition products as it seeks to become a comprehensive pet healthcare player.

The health functional food market is already mature and populated by large pharmaceutical and food companies, meaning differentiation of its "Jayeonpore" ingredients will be key for the company as a later entrant.

In new drug development, the Burixafor combination-therapy collaboration with US-based Exicure is the flagship example, targeting multiple hematologic and solid tumor indications with a preclinical-stage CXCR4 antagonist, though the path to clinical entry will take time.

The bio R&D, genetic engineering, drug delivery system, nanotech diagnostics/therapeutics, and CSO fields the company declared entry into via its June articles-of-incorporation amendment are each already competitive markets with established specialized players, leaving track-record building as a challenge for the new entrant.

Alongside the June 2026 launch of its new CEO regime, the company added bio R&D, medical/healthcare, animal healthcare, and digital platform as new business purposes, backing this with a completed KRW 13.3 billion third-party equity placement and sequential KRW 3.0 billion and KRW 10.0 billion convertible bond issuances.

The KRW 10.0 billion (11th) CB explicitly stated its purpose as funding for acquiring securities in other companies, though the company noted the specific acquisition target had not yet been finalized and would be disclosed separately once determined.

Indeed, on July 3, 2026 a contract to acquire a 12.28% stake in an unspecified unlisted company for about KRW 9.97 billion was disclosed, indicating the equity-investment phase of the new-business expansion has moved into execution.

On the pipeline side, the Burixafor combination therapy with US-based Exicure is proceeding through in-vivo validation and translational research/biomarker development toward an Investigational New Drug (IND) filing, with the company noting that hematologic indications could potentially enter Phase 2 directly if the program is scaled up.

In the existing business, sporadic recurrence of livestock diseases such as avian influenza continues to support demand for stronger biosecurity and antibody-based response technologies, while the pet healthcare segment is seeking to expand overseas supply on the back of its US FDA food facility registration.

That said, most of the newly declared business purposes have yet to translate into concrete revenue and remain at an early stage, and given the ongoing large-scale fund-raising, it will be important to sequentially track confirmation of M&A targets, pipeline progress, and changes to the capital-raising structure.